Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: GlobeNewswire
GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the Company’s GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH), on Thursday, December 5th at 11am Eastern Time. The call will feature a presentation by Stephen A. Harrison, MD (Pinnacle Clinical Research), a leading expert in the field of NASH, who will provide an overview of current and future treatment approaches for this disorder. Dr. Harrison will be available to answer questions at the conclusion of the call. The meeting will also feature a presentation by Altimmune's management team, which will provide an update on their NASH product candidate, ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist. As demonstrated in relevant animal models, ALT-801 is capable of inducing significant weight loss and treating the ob
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024GlobeNewswire
- Altimmune to Participate at Two Upcoming ConferencesGlobeNewswire
- Altimmune, Inc. (NASDAQ: ALT) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.MarketBeat
- Altimmune Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Global COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023 [Yahoo! Finance]Yahoo! Finance
ALT
Earnings
- 3/27/24 - Miss
ALT
Sec Filings
- 4/10/24 - Form SC
- 3/27/24 - Form S-8
- 3/27/24 - Form 10-K
- ALT's page on the SEC website